| A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis AB Begovich, VEH Carlton, LA Honigberg, SJ Schrodi, AP Chokkalingam, ... The American Journal of Human Genetics 75 (2), 330-337, 2004 | 1874 | 2004 |
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy LA Honigberg, AM Smith, M Sirisawad, E Verner, D Loury, B Chang, S Li, ... Proceedings of the National Academy of Sciences 107 (29), 13075-13080, 2010 | 1736 | 2010 |
| Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase Z Pan, H Scheerens, SJ Li, BE Schultz, PA Sprengeler, LC Burrill, ... ChemMedChem 2 (1), 58-61, 2007 | 839 | 2007 |
| Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials FG Holz, SR Sadda, B Busbee, EY Chew, P Mitchell, A Tufail, C Brittain, ... JAMA ophthalmology 136 (6), 666-677, 2018 | 335 | 2018 |
| Inhibitors of bruton's tyrosine kinase L Honigberg, E Verner, Z Pan US Patent 7,514,444, 2009 | 335* | 2009 |
| Inhibitors of bruton's tyrosine kinase L Honigberg, E Verner, Z Pan US Patent 7,825,118, 2010 | 325* | 2010 |
| Identification of substrates of human protein-tyrosine phosphatase PTPN22 J Wu, A Katrekar, LA Honigberg, AM Smith, MT Conn, J Tang, D Jeffery, ... Journal of Biological Chemistry 281 (16), 11002-11010, 2006 | 296 | 2006 |
| Effect of selective LRRK2 kinase inhibition on nonhuman primate lung RN Fuji, M Flagella, M Baca, MA S. Baptista, J Brodbeck, BK Chan, ... Science translational medicine 7 (273), 273ra15-273ra15, 2015 | 292 | 2015 |
| Neuronal cell migration in C. elegans: regulation of Hox gene expression and cell position J Harris, L Honigberg, N Robinson, C Kenyon Development 122 (10), 3117-3131, 1996 | 229 | 1996 |
| Inhibitors of bruton's tyrosine kinase L Honigberg, E Verner, Z Pan US Patent App. 11/692,870, 2008 | 223 | 2008 |
| ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease JL Cummings, S Cohen, CH van Dyck, M Brody, C Curtis, W Cho, M Ward, ... Neurology 90 (21), e1889-e1897, 2018 | 222 | 2018 |
| Bruton's tyrosine kinase activity probe and method of using Z Pan, SJ Li, H Scheerens, L Honigberg, E Verner US Patent 8,987,233, 2015 | 215 | 2015 |
| Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration BL Yaspan, DF Williams, FG Holz, CD Regillo, Z Li, A Dressen, ... Science translational medicine 9 (395), eaaf1443, 2017 | 187 | 2017 |
| Inhibitors of brutons tyrosine kinase L Honigberg, E Verner, Z Pan, TD Mody US Patent 8,088,781, 2012 | 185 | 2012 |
| Inhibitors of bruton's tyrosine kinase L Honigberg, E Verner, Z Pan US Patent 8,008,309, 2011 | 179 | 2011 |
| Inhibitors of bruton's tyrosine kinase L Honigberg, E Verner, Z Pan US Patent App. 12/499,008, 2010 | 159 | 2010 |
| Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors L Honigberg, E Verner, J Buggy, D Loury, W Chen US Patent App. 13/003,811, 2011 | 157 | 2011 |
| Inhibitors of Bruton's tyrosine kinase L Honigberg, E Verner, Z Pan US Patent 8,501,751, 2013 | 152 | 2013 |
| Inhibitors of b lymphocyte kinase L Honigberg, EJ Verner, JJ Buggy, DJ Loury, W Chen US Patent App. 13/404,422, 2012 | 146 | 2012 |
| Inhibitors of bruton's tyrosine kinase L Honigberg, E Verner, Z Pan US Patent App. 13/162,449, 2011 | 137 | 2011 |
